Bioceres Crop Solutions (NASDAQ:BIOX) PT Lowered to $13.00

Bioceres Crop Solutions (NASDAQ:BIOX) had its price target reduced by Oppenheimer from $16.00 to $13.00 in a report issued on Monday morning, Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

BIOX has been the subject of several other reports. Roth Capital raised shares of Bioceres Crop Solutions to a “strong-buy” rating in a research note on Tuesday, July 2nd. Lake Street Capital decreased their price target on Bioceres Crop Solutions from $25.00 to $13.00 and set a “buy” rating for the company in a research note on Wednesday, September 11th. Canaccord Genuity Group raised Bioceres Crop Solutions to a “strong-buy” rating in a research report on Friday, July 19th. Roth Mkm cut their price target on Bioceres Crop Solutions from $15.00 to $13.00 and set a “buy” rating for the company in a report on Wednesday, September 11th. Finally, Canaccord Genuity Group lowered their price objective on Bioceres Crop Solutions from $12.50 to $10.00 and set a “buy” rating on the stock in a research note on Thursday, October 17th. Four analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $12.25.

Bioceres Crop Solutions Trading Down 3.9 %

Shares of Bioceres Crop Solutions stock opened at $6.98 on Monday. The company has a market capitalization of $438.32 million, a P/E ratio of 705.00 and a beta of 0.47. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.28 and a quick ratio of 0.91. Bioceres Crop Solutions has a 1 year low of $6.98 and a 1 year high of $14.05. The business has a 50 day moving average price of $8.76 and a 200 day moving average price of $10.41.

Bioceres Crop Solutions (NASDAQ:BIOX) last issued its quarterly earnings data on Monday, September 9th. The company reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.23). Bioceres Crop Solutions had a return on equity of 0.93% and a net margin of 0.68%. The firm had revenue of $124.30 million during the quarter, compared to analyst estimates of $126.75 million. During the same quarter in the prior year, the firm earned ($0.06) EPS. Sell-side analysts anticipate that Bioceres Crop Solutions will post 0.39 EPS for the current fiscal year.

Institutional Trading of Bioceres Crop Solutions

Institutional investors have recently modified their holdings of the business. Oppenheimer & Co. Inc. bought a new position in shares of Bioceres Crop Solutions during the 1st quarter worth about $139,000. Lazard Asset Management LLC bought a new position in shares of Bioceres Crop Solutions during the 1st quarter worth approximately $212,000. Ping Capital Management Inc. bought a new position in shares of Bioceres Crop Solutions during the 2nd quarter worth approximately $448,000. Sumitomo Mitsui Trust Holdings Inc. bought a new position in shares of Bioceres Crop Solutions during the 2nd quarter worth approximately $472,000. Finally, Dimensional Fund Advisors LP lifted its position in shares of Bioceres Crop Solutions by 9.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 61,330 shares of the company’s stock worth $688,000 after buying an additional 5,341 shares in the last quarter. Institutional investors own 17.68% of the company’s stock.

About Bioceres Crop Solutions

Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through Seed and Integrated Products, Crop Protection, and Crop Nutrition segments. The Seed and Integrated Products segment provides seed traits, germplasms, and seed treatment packs for healthier, and higher yielding crops.